Skip to main content
Retour
ASND logo

Ascendis Pharma A/S

Qualité des données : 100%
ASND
NASDAQ Healthcare Biotechnology
215,54 €
▼ 2,52 € (-1,16%)
Cap. Boursière : 13,23B
Fourchette du Jour
212,60 € 219,18 €
Fourchette 52 Semaines
124,06 € 248,60 €
Volume
253 600
Moyenne 50J / 200J
225,73 € / 202,09 €
Clôture Précédente
218,06 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -60,4 0,3
P/B 2,9
ROE % 3,7
Net Margin % -31,7 3,8
Rev Growth 5Y % 207,1 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
287,17 € +33.2%
Low: 250,00 € High: 342,00 €
P/E Prévisionnel
51,7
BPA Prévisionnel
4,22 €
Croissance BPA (est.)
+0,0%
CA Est.
1,4 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 23,00 €
19,34 € – 26,46 €
3,4 B 5
FY2029 20,07 €
16,87 € – 23,08 €
3,1 B 2
FY2028 15,87 €
10,83 € – 21,46 €
2,5 B 7

Points Clés

Revenue grew 207,09% annually over 5 years — strong growth
Generating 43,62M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 116,87%
Capital efficient — spends only 1,18% of revenue on capex

Croissance

Revenue Growth (5Y)
207,09%
Revenue (1Y)90,22%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-13,85%
Net Margin-31,67%
Op. Margin-18,92%

Sécurité

Debt / Equity
N/A
Current Ratio1,04
Interest Coverage-1,69

Valorisation

P/E Ratio
-60,40
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 90,22% Revenue Growth (3Y) 61,04%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 207,09% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 691,71M Net Income (TTM) -219,03M
ROE N/A ROA -16,82%
Gross Margin 85,08% Operating Margin -18,92%
Net Margin -31,67% Free Cash Flow (TTM) 43,62M
ROIC -13,85% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,04
Interest Coverage -1,69 Dividend Yield 0,00%
Valuation
P/E Ratio -60,40 P/B Ratio N/A
P/S Ratio 19,13 PEG Ratio 1,13
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 13,23B Enterprise Value 13,49B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 691,71M 363,64M 266,72M 51,17M 7,78M
Net Income -219,03M -378,08M -481,45M -583,19M -383,58M
EPS (Diluted) -3,62 -6,53 -8,55 -10,40 -7,00
Gross Profit 588,53M 319,38M 222,32M 39,04M 4,26M
Operating Income -130,89M -278,76M -455,54M -561,81M -451,79M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,30B 1,18B 825,59M 1,09B 1,08B
Total Liabilities 1,46B 1,29B 971,28M 826,39M 201,29M
Shareholders' Equity -162,75M -105,71M -145,70M 263,35M 883,64M
Total Debt 871,41M 856,62M 743,06M 617,57M 209,92M
Cash & Equivalents 615,78M 559,54M 392,16M 444,77M 446,27M
Current Assets 1,11B 1,06B 702,72M 923,47M 805,89M
Current Liabilities 1,07B 907,86M 736,51M 716,78M 100,36M